Australia's largest stock trading and investment forum Australia's #1 stock forum

NEU

Click for more information

0.00%

$17.09 neuren pharmaceuticals limited

The highest rated post today, and deservedly so, is TripAce’s...

First 44 Last

Share
Profile

Follow
hottod

5,896 Posts.

17676

07/08/24

17:29

Post #: 75113400
Share
Originally posted by TripAces ↑

E & P Commentary:

Impact to NEU

ACAD is trading down ~11% in the aftermarket

Consensus will likely downgrade NEU’s full year royalty earnings by ~10%

It is important to note that NEU are only exposed to 10% of the impact of ACAD’s sales of DAYBUE

And NEU will still be eligible for the US$50M (~A$77M) milestone payment (assuming DAYBUE crosses $250M of net sales in 2024; which is still very likely)

Total FY24 revenue from licensing for NEU is still estimated at ~A$135M, with the potential for another ~US$33M should ACAD sell their paediatric rare disease priority review voucher (RPDPRV)

As such the estimated reduction on overall full year revenue for NEU (vs E&P estimates), is only ~4.5% (excluding RPDPRV)

Therefore, if the market reacts negatively to NEU by more than ~5% to today’s news from ACAD, and given the thesis around DAYBUE and NNZ-2591 remains solid (see more details below), a buying opportunity may emerge.

ACAD Earnings and Guidance

2Q24 DAYBUE net product sales is a 6% miss to VA consensus (US$89.7M) and a 4% miss vs E&Pf (US$88.4M).

The FY earnings downgrade is ~10% vs prior guidance at the midpoint, but the new range is 40% tighter – suggesting greater confidence

Management gave mixed feedback about currently tracking towards the lower end of guidance, but with the aim of reaching the upper end should their HCP and caregiver education and support initiatives play out as anticipated

The reason for the change in guidance is due to slower new patient starts than expected.

11% sequential growth in DAYBUE sales comes from 7% patient volumes and 4% price increase.

Patient Numbers are Flat

Total patients using DAYBUE has increased since May (862; which was after a down period) to 900 on the 1^st August 2024. But is flat versus the end of 2023.

Patient numbers are 20% below E&Pf, and is attributed to a slower rate of new starts – particularly in the high volume and community neurology practices (which account for 65% of Rett patients)

30% of all registered Rett patients in the US have initiated treatment, leaving 70% still addressable, and this number will grow with improved diagnostics and awareness

Underlying Metrics Look Positive

Trends in: new patient additions (12% higher weekly rate); discontinuations (46% lower weekly rate); Net patient adds (900 patients at Aug 1 vs 862 on May 3^rd), are all heading in the right direction

Importantly, the 900 current patients are recipients of enhanced care protocols, leveraging the progress made in GI management.

The more recently added patients are more likely than the equivalent 900 patients (at the end of Dec’23) to remain on the drug past the first 2-4 weeks, and are therefore more likely to experience positive impact of the treatment.

>80% of payers have written policies in place with ~90% conversion to paid over time. This suggests that the level of evidence provided by the company and doctors is satisfying payers as to the level of health economic value provided by the drug

Market research has shown that 92% of healthcare providers (HCPs) are aware of DAYBUE, all 100% are covered by ACAD salesforce, and 30% have initiated treatment. Doctors surveyed have stated an intent to treat with DAYBUE for >70% of eligible patients (vs respondents’ current level of ~40%) – suggesting further increases in uptake will come through in the coming months

Persistency is continuing to track ~10pp higher than the open label extension (LILAC-1) with real world persistency at 9 months at 58%. This remains in line with our forecast for long term persistency at ~50%.

Supportive Long Term and Real-World Data

Poster and paper publications are supportive of long-term efficacy consistent with trial experience.

Importantly, real-world improvements in clinical management are manifesting with more manageable gasto-intestinal side-effects

These data now being available in formats that are digestible to HCPs, payers, and caregivers will help ACAD’s team to disseminate and spread awareness and education

Gross to Net

ACAD took a small price increase midway through Q2 (4% of the 11% in sequential growth)

Overall compliance to dose remains at ~75% in line with our original assunmptions

Product consumption rate across the entire population is in the low 70% range

International Expansion of DAYBUE

Canada: Aiming for approval around year-end 2024

Europe: Expecing a Marketing Authorisation Application (MAA) filing in Q1 2025

Japan: Will require a small study involving Japanese patients, discussion are ongoing

NNZ-2591

ACAD are proceding with pipeline developmet of ACP-2591 (formerly NNZ-2591) in Rett and Fragile X.

It is conceivable that an ACAD’s Rett study could occur outside the US, to avoid cannibalisation of DAYBUE. We view Australia as a good option in this regard and have comunicated this to ACAD managemnet

NEU are awaiting top line result from their Phase 2 study of NNZ-2591 in Angelman Syndrome (N.B. This is now expected in the coming days)

NEU also have an end of Phase 2 meeting for Phelan-McDermid syndrome with the FDA scheduled for Sept’2024, which will also be informative of their Pitt Hopkins program.

Placebo controlled studies of NNZ-2591 would help to build value and confidence, with a Phase 3 in Phelan-McDermid most likley in the first instance.

Expand

The highest rated post today, and deservedly so, is TripAce’s copy of commentary by David Nayagam at Evans and Partners.

The E & P summary demonstrates understanding of Neuren and its assets, presents all the relevant facts and steers clear of exaggeration or emotional reaction.

I won’t rehash what’s been said by E & P.

Instead, I want to highlight Q2 sales of Skyclarys, which were announced last week by Biogen. Skyclarys was acquired through Biogen’s US$7.3bn takeover of Reata last year. Skyclarys, which treats a rare neurology disease with a patient population similar to Rett syndrome, was approved by the FDA just before DayBue was approved.

Biogen and the financial commentators seem to be very pleased with how Skyclarys is going.

Below are quotes from coverage of the results by four different publications

Viehbacher said the launch of Skyclarys is going “extremely well.”

Strong sales of new launches, including rare disease therapy Skyclarys, helped buoy Biogen’s Q2 earnings.

The strong sales of Skyclarys and Tysabri, which both outperformed market expectations, contributed to this robust financial outcome…

Leqembi for early Alzheimer’s, Skyclarys for Friedreich’s ataxia and Zurzuvae for postpartum depression meet or exceed Biogen’s internal sales expectations.

So what were the Skyclarys sales? Excluding sales in Europe which have now begun to contribute to earnings, the US sales in Q2 2024 were US$75.6m compared with US$73m in Q1.

In comparison, DayBue US sales in Q2 2024 were US$84.6m, compared with US$75.9m in Q1.
NEU Price at posting: $17.09 Sentiment: Hold Disclosure: Held
102 Upvote

28 Great analysis

Reply

Top Stories

Largest drill campaign to begin: Saturn Metals at Diggers & Dealers

Astute sniffs 1,260 ppm lithium and thick mineralisation in Nevada

From the Floor with Kim Beazley at Diggers and Dealers 2024

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Revolutionary inverter technology leads the clean energy charge

There are more pages in this discussion • 4 more messages in this thread...

First 44 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $17.09		Change 0.000(0.00%)		Mkt cap ! $2.184B

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	582	$17.95

Sellers (Offers)

Price($)	Vol.	No.
$14.00	1600	1

View Market Depth

No.	Vol.	Price($)
2	582	17.950
1	550	17.500
1	100	17.150
1	877	17.090
1	100	17.050

Price($)	Vol.	No.
14.000	1600	1
14.990	1786	1
15.000	4229	4
15.250	900	1
15.290	1655	1

Last trade - 16.36pm 07/08/2024 (20 minute delay)

NEU (ASX) Chart

Day chart unavailable